# TriSalus Life Sciences, Inc.: financial statements, quarterly

TLSI · Nasdaq · CIK 1826667 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tlsi.md) · [Financials](/companies/tlsi/financials.md) · [Filings](/companies/tlsi/filings.md) · [Insiders](/companies/tlsi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tlsi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [5.2](/filings/0001826667-24-000051.md) | [5.7 d](/filings/0001826667-25-000070.md) | [6.5](/filings/0001826667-25-000051.md) | [7.4](/filings/0001826667-25-000117.md) | [7.3](/filings/0001628280-25-052043.md) | [8.3 d](/filings/0001628280-26-015163.md) | [9.2](/filings/0001628280-26-034100.md) | [11.2](/filings/0001628280-26-054275.md) | [11.6](/filings/0001628280-25-052043.md) | [13.2 d](/filings/0001628280-26-015163.md) | [8.9](/filings/0001628280-26-034100.md) | [11.4](/filings/0001628280-26-054275.md) |
| Cost of revenue | $m | [0.6](/filings/0001826667-24-000051.md) | [0.6 d](/filings/0001826667-25-000070.md) | [1.0](/filings/0001826667-25-000051.md) | [0.9](/filings/0001826667-25-000117.md) | [1.0](/filings/0001628280-25-052043.md) | [1.2 d](/filings/0001628280-26-015163.md) | [1.5](/filings/0001628280-26-034100.md) | [1.8](/filings/0001628280-26-054275.md) | [1.9](/filings/0001628280-25-052043.md) | [1.8 d](/filings/0001628280-26-015163.md) | [1.2](/filings/0001628280-26-034100.md) | [1.5](/filings/0001628280-26-054275.md) |
| Gross profit | $m | [4.6](/filings/0001826667-24-000051.md) | [5.1 d](/filings/0001826667-25-000070.md) | [5.5](/filings/0001826667-25-000051.md) | [6.5](/filings/0001826667-25-000117.md) | [6.3](/filings/0001628280-25-052043.md) | [7.0 d](/filings/0001628280-26-015163.md) | [7.7](/filings/0001628280-26-034100.md) | [9.4](/filings/0001628280-26-054275.md) | [9.7](/filings/0001628280-25-052043.md) | [11.4 d](/filings/0001628280-26-015163.md) | [7.7](/filings/0001628280-26-034100.md) | [9.9](/filings/0001628280-26-054275.md) |
| Research and development | $m | [9.5](/filings/0001826667-24-000051.md) | [7.8 d](/filings/0001826667-25-000070.md) | [5.8](/filings/0001826667-25-000070.md) | [4.7](/filings/0001826667-25-000117.md) | [4.2](/filings/0001628280-25-052043.md) | [3.0 d](/filings/0001628280-26-015163.md) | [3.0](/filings/0001628280-26-034100.md) | [3.7](/filings/0001628280-26-054275.md) | [5.2](/filings/0001628280-25-052043.md) | [2.6 d](/filings/0001628280-26-015163.md) | [3.2](/filings/0001628280-26-034100.md) | [3.1](/filings/0001628280-26-054275.md) |
| Operating income | $m | [(18.6)](/filings/0001826667-24-000051.md) | [(14.2) d](/filings/0001826667-25-000070.md) | [(11.7)](/filings/0001826667-25-000070.md) | [(8.2)](/filings/0001826667-25-000117.md) | [(8.7)](/filings/0001628280-25-052043.md) | [(7.6) d](/filings/0001628280-26-015163.md) | [(7.3)](/filings/0001628280-26-034100.md) | [(7.3)](/filings/0001628280-26-054275.md) | [(9.0)](/filings/0001628280-25-052043.md) | [(3.3) d](/filings/0001628280-26-015163.md) | [(8.4)](/filings/0001628280-26-034100.md) | [(9.8)](/filings/0001628280-26-054275.md) |
| Interest expense | $m | [0.0](/filings/0001826667-23-000007.md) | [0.0 d](/filings/0001826667-24-000005.md) | [0.0](/filings/0001826667-24-000017.md) | [0.9](/filings/0001826667-24-000039.md) | [1.1](/filings/0001628280-25-052043.md) | [1.1 d](/filings/0001628280-26-015163.md) | [1.2](/filings/0001628280-26-034100.md) | [1.4](/filings/0001628280-26-054275.md) | [1.5](/filings/0001628280-25-052043.md) | [1.5 d](/filings/0001628280-26-015163.md) | [1.4](/filings/0001628280-26-034100.md) | [1.5](/filings/0001628280-26-054275.md) |
| Income tax | $m | [0.0](/filings/0001826667-24-000051.md) | [0.0 d](/filings/0001826667-25-000070.md) | [0.0](/filings/0001826667-25-000051.md) | [0.0](/filings/0001826667-25-000117.md) | [(0.0)](/filings/0001628280-25-052043.md) | [(0.0) d](/filings/0001628280-26-015163.md) | [0.0](/filings/0001628280-26-034100.md) | [(0.0)](/filings/0001628280-26-054275.md) | [0.0](/filings/0001628280-25-052043.md) | [0.0 d](/filings/0001628280-26-015163.md) | [0.0](/filings/0001628280-26-034100.md) | [0.0](/filings/0001628280-26-054275.md) |
| Net income | $m | [(1.4)](/filings/0001826667-24-000051.md) | [(35.6) d](/filings/0001826667-25-000070.md) | [(13.2)](/filings/0001628280-25-052043.md) | [(4.3)](/filings/0001628280-25-052043.md) | [(2.4)](/filings/0001628280-25-052043.md) | [(10.1) d](/filings/0001628280-26-015163.md) | [(10.4)](/filings/0001628280-26-054275.md) | [(8.3)](/filings/0001628280-26-054275.md) | [(10.8)](/filings/0001628280-25-052043.md) | [(9.8) d](/filings/0001628280-26-015163.md) | [1.5](/filings/0001628280-26-054275.md) | [(9.2)](/filings/0001628280-26-054275.md) |
| Diluted EPS | $ per share | [(0.14)](/filings/0001826667-24-000051.md) | not reported | [(0.60)](/filings/0001826667-25-000070.md) | [(0.21)](/filings/0001826667-25-000117.md) | [(0.12)](/filings/0001628280-25-052043.md) | not reported | [(0.39)](/filings/0001628280-26-034100.md) | [(0.27)](/filings/0001628280-26-054275.md) | [(0.96)](/filings/0001628280-25-052043.md) | not reported | [0.03](/filings/0001628280-26-034100.md) | [(0.16)](/filings/0001628280-26-054275.md) |
| Basic EPS | $ per share | [(0.14)](/filings/0001826667-24-000051.md) | not reported | [(0.60)](/filings/0001826667-25-000070.md) | [(0.21)](/filings/0001826667-25-000117.md) | [(0.12)](/filings/0001628280-25-052043.md) | not reported | [(0.39)](/filings/0001628280-26-034100.md) | [(0.27)](/filings/0001628280-26-054275.md) | [(0.96)](/filings/0001628280-25-052043.md) | not reported | [0.03](/filings/0001628280-26-034100.md) | [(0.16)](/filings/0001628280-26-054275.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [21.4](/filings/0001826667-23-000007.md) | [11.8](/filings/0001826667-25-000070.md) | [4.0](/filings/0001826667-24-000017.md) | [16.5](/filings/0001826667-24-000039.md) | [11.3](/filings/0001826667-24-000051.md) | [8.5](/filings/0001628280-26-015163.md) | [13.0](/filings/0001826667-25-000051.md) | [26.5](/filings/0001826667-25-000117.md) | [22.7](/filings/0001628280-25-052043.md) | [20.4](/filings/0001628280-26-054275.md) | [56.6](/filings/0001628280-26-034100.md) | [46.3](/filings/0001628280-26-054275.md) |
| Current assets | $m | [29.0](/filings/0001826667-23-000007.md) | [20.9](/filings/0001826667-25-000070.md) | [13.2](/filings/0001826667-24-000017.md) | [27.9](/filings/0001826667-24-000039.md) | [23.8](/filings/0001826667-24-000051.md) | [20.7](/filings/0001628280-26-015163.md) | [25.1](/filings/0001826667-25-000051.md) | [38.1](/filings/0001826667-25-000117.md) | [33.3](/filings/0001628280-25-052043.md) | [32.2](/filings/0001628280-26-054275.md) | [68.1](/filings/0001628280-26-034100.md) | [59.7](/filings/0001628280-26-054275.md) |
| Total assets | $m | [33.6](/filings/0001826667-23-000007.md) | [24.6](/filings/0001826667-25-000070.md) | [17.9](/filings/0001826667-24-000017.md) | [32.4](/filings/0001826667-24-000039.md) | [27.5](/filings/0001826667-24-000051.md) | [24.0](/filings/0001628280-26-015163.md) | [28.6](/filings/0001826667-25-000051.md) | [41.3](/filings/0001826667-25-000117.md) | [36.5](/filings/0001628280-25-052043.md) | [35.3](/filings/0001628280-26-054275.md) | [71.0](/filings/0001628280-26-034100.md) | [62.4](/filings/0001628280-26-054275.md) |
| Current liabilities | $m | [9.3](/filings/0001826667-23-000007.md) | [14.7](/filings/0001826667-25-000070.md) | [14.4](/filings/0001826667-24-000017.md) | [12.0](/filings/0001826667-24-000039.md) | [9.9](/filings/0001826667-24-000051.md) | [10.2](/filings/0001628280-26-015163.md) | [11.8](/filings/0001826667-25-000051.md) | [9.3](/filings/0001826667-25-000117.md) | [10.9](/filings/0001628280-25-052043.md) | [11.5](/filings/0001628280-26-054275.md) | [11.8](/filings/0001628280-26-034100.md) | [11.2](/filings/0001628280-26-054275.md) |
| Total liabilities | $m | [25.1](/filings/0001826667-23-000007.md) | [51.7](/filings/0001826667-25-000070.md) | [52.8](/filings/0001826667-24-000017.md) | [56.6](/filings/0001826667-24-000039.md) | [47.9](/filings/0001826667-24-000051.md) | [49.9](/filings/0001628280-26-015163.md) | [63.0](/filings/0001826667-25-000051.md) | [60.7](/filings/0001826667-25-000117.md) | [63.2](/filings/0001628280-25-052043.md) | [69.2](/filings/0001628280-26-054275.md) | [58.2](/filings/0001628280-26-034100.md) | [55.9](/filings/0001628280-26-054275.md) |
| Long-term debt | $m | not reported | [0.0](/filings/0001826667-25-000070.md) | not reported | [21.3](/filings/0001826667-24-000039.md) | [21.7](/filings/0001826667-24-000051.md) | [22.1](/filings/0001628280-26-015163.md) | [31.7](/filings/0001826667-25-000051.md) | [32.3](/filings/0001826667-25-000117.md) | [32.8](/filings/0001628280-25-052043.md) | [33.0](/filings/0001628280-26-054275.md) | [33.1](/filings/0001628280-26-034100.md) | [33.1](/filings/0001628280-26-054275.md) |
| Shareholders' equity | $m | [8.3](/filings/0001826667-24-000051.md) | [(27.1)](/filings/0001628280-26-015163.md) | [(36.0)](/filings/0001628280-25-052043.md) | [(25.3)](/filings/0001628280-25-052043.md) | [(20.4)](/filings/0001628280-25-052043.md) | [(25.9)](/filings/0001628280-26-054275.md) | [(34.4)](/filings/0001628280-26-054275.md) | [(19.4)](/filings/0001628280-26-054275.md) | [(26.7)](/filings/0001628280-25-052043.md) | [(33.9)](/filings/0001628280-26-054275.md) | [12.8](/filings/0001628280-26-054275.md) | [6.6](/filings/0001628280-26-054275.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(21.7) d](/filings/0001826667-24-000051.md) | [(9.2) d](/filings/0001826667-25-000070.md) | [(10.9)](/filings/0001826667-25-000070.md) | [(13.4) d](/filings/0001826667-25-000117.md) | [(10.8) d](/filings/0001628280-25-052043.md) | [(5.7) d](/filings/0001628280-26-015163.md) | [(4.5)](/filings/0001628280-26-034100.md) | [(7.3) d](/filings/0001628280-26-054275.md) | [(3.7) d](/filings/0001628280-25-052043.md) | [(2.5) d](/filings/0001628280-26-015163.md) | [(6.5)](/filings/0001628280-26-034100.md) | [(10.1) d](/filings/0001628280-26-054275.md) |
| Capital expenditure | $m | [0.2 d](/filings/0001826667-24-000051.md) | [0.4 d](/filings/0001826667-25-000070.md) | [0.1](/filings/0001826667-25-000051.md) | [0.1 d](/filings/0001826667-25-000117.md) | [0.2 d](/filings/0001628280-25-052043.md) | [0.1 d](/filings/0001628280-26-015163.md) | [0.8](/filings/0001628280-26-034100.md) | [(0.1) d](/filings/0001628280-26-054275.md) | [0.2 d](/filings/0001628280-25-052043.md) | [0.0 d](/filings/0001628280-26-015163.md) | [0.1](/filings/0001628280-26-034100.md) | [0.1 d](/filings/0001628280-26-054275.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.3](/filings/0001826667-23-000007.md) | [16.2](/filings/0001826667-24-000017.md) | [0.4](/filings/0001826667-24-000039.md) | [13.2](/filings/0001826667-24-000051.md) | [23.3](/filings/0001826667-25-000051.md) | [23.9](/filings/0001826667-25-000117.md) | [26.5](/filings/0001628280-25-052043.md) | [28.5](/filings/0001628280-26-034100.md) | [32.9](/filings/0001628280-26-054275.md) | [43.1](/filings/0001628280-25-052043.md) | [52.3](/filings/0001628280-26-034100.md) | [58.3](/filings/0001628280-26-054275.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 61,574,600 at 2026-08-04, from the cover of the [10-Q filed 2026-08-06](/filings/0001628280-26-054275.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.